Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 1/20 | 0.48 |
| ▸ | SYNJ2 | O15056 | 2/20 | 0.41 |
| ▸ | ATP1A1 | P05023 | 5/20 | 0.38 |
| ▸ | ATP1B1 | P05026 | 5/20 | 0.38 |
| ▸ | ATP1A3 | P13637 | 5/20 | 0.38 |
| ▸ | ATP1B2 | P14415 | 5/20 | 0.38 |
| ▸ | ATP1A2 | P50993 | 5/20 | 0.38 |
| ▸ | ATP1B3 | P54709 | 5/20 | 0.38 |
| ▸ | FXYD2 | P54710 | 5/20 | 0.38 |
| ▸ | ATP1A4 | Q13733 | 5/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | F3 | P13726 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL527086 | 0.74 | SELP (0.45) | SELPSYNJ2HSD11B1F3 | |
| SCHEMBL29993031 | 0.74 | SELP (0.45) | SELPSYNJ2HSD11B1F3 | |
| SCHEMBL30723000 | 0.70 | HSD11B1 (0.62) | SELPSYNJ2HSD11B1PTPN1MEN1 | |
| SCHEMBL29993378 | 0.70 | SELP (0.44) | SELPSYNJ2ATP1A1ATP1B1ATP1A3 | |
| SCHEMBL31447869 | 0.67 | SELP (0.47) | SELPSYNJ2HSD11B1PTPN1F3 | |
| SCHEMBL30111361 | 0.67 | HSD11B1 (0.56) | HSD11B1PTPN1MEN1KMT2A | |
| SCHEMBL21012995 | 0.66 | PTPN1 (0.57) | SYNJ2PTPN1MEN1KMT2A | |
| SCHEMBL7688096 | 0.66 | PTPN1 (0.57) | SYNJ2PTPN1MEN1KMT2A | |
| SCHEMBL20097839 | 0.66 | PTPN1 (0.57) | SYNJ2PTPN1MEN1KMT2A | |
| SCHEMBL11288598 | 0.66 | PTPN1 (0.57) | SYNJ2PTPN1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122038156-A | Method for improving rhodozyma astaxanthin yield based on transcription factor expression regulation | 中国科学院青岛生物能源与过程研究所 | 2026-05-15 | — | — | CN | claimed |
| CN-120090978-A | Gateway optimization management system and scheduling method for multi-atomic task request | 兴唐通信科技有限公司 | 2025-06-03 | — | — | CN | claimed |
| CN-118260433-A | 3D map display interaction method based on electric power knowledge map | 国网信通亿力科技有限责任公司 | 2024-06-28 | — | — | CN | claimed |
| CN-116455400-A | Parallel ANS coding method and decoding method for reducing decoding error propagation | 上海理工大学 | 2023-07-18 | — | — | CN | claimed |
| CN-116128125-A | Thermal power plant operation benefit maximization optimizing system | 国能粤电台山发电有限公司 | 2023-05-16 | — | — | CN | claimed |
| CN-114330279-B | Cross-modal semantic consistency recovery method | 电子科技大学 | 2023-04-18 | — | — | CN | claimed |
| CN-112910841-B | Industrial control network intrusion intelligent sensing method based on fuzzy matching | 国网上海市电力公司 | 2022-11-29 | — | — | CN | claimed |
| CN-122038156-A | Method for improving rhodozyma astaxanthin yield based on transcription factor expression regulation | 中国科学院青岛生物能源与过程研究所 | 2026-05-15 | — | — | CN | disclosed |
| WO-2026099807-A1 | TYPE-I INTERFERON RESPONSE AND EXHAUSTION GENE SIGNATURE AS A BIOMARKER FOR CANCER IMMUNOTHERAPY | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12590815-B2 | VSLAM with image buffer and extraction | SOCIONEXT INC. (JP) | 2026-03-31 | — | — | US | disclosed |
| US-12541811-B2 | Tile-based primitive rendering method and apparatus according to lane masks, computer device and storage medium | GLENFLY TECH CO., LTD. (CN) | 2026-02-03 | — | — | US | disclosed |
| US-12401300-B2 | Deterministic control of sensor based motor | CYPRESS SEMICONDUCTOR CORPORATION (US) | 2025-08-26 | — | — | US | disclosed |
| CN-120117964-A | Method, system and application for preparing electronic grade isopropanol by acetone hydrogenation | 中国石油化工股份有限公司 | 2025-06-10 | — | — | CN | disclosed |
| CN-109273738-B | Method for controlling a fuel cell vehicle | 现代自动车株式会社 | 2022-06-10 | — | — | CN | disclosed |
| US-20220156653-A1 | Goals Assembly Layers | ABELOW DANIEL H (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220149653-A1 | POWER CONTROL SYSTEM (PCS) COMMISSIONING AGENT | ASCO POWER TECHNOLOGIES. L.P. | 2022-05-12 | — | — | US | disclosed |
| CN-114442518-A | Power Control System (PCS) sequencer | ASCO动力技术公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-108885660-B | Techniques for metadata processing | 查尔斯斯塔克德雷珀实验室有限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-114168316-A | Video memory allocation processing method, device, equipment and system | 支付宝(杭州)信息技术有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-113964146-A | Image sensing device including protection device | 爱思开海力士有限公司 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12541811-B2 | Tile-based primitive rendering method and apparatus according to lane masks, computer device and storage medium | AXL, BAG2, TBKBP1 | SELP 3437/4885SYNJ2 1859/4885ATP1A1 3219/4885 |
| US-12590815-B2 | VSLAM with image buffer and extraction | VCL, VAPA, LSM8 | SELP 1218/4885SYNJ2 3405/4885ATP1A1 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.